The public FDA record for this applicant is a single 510(k) clearance. K262885 covers a 308nm Ultraviolet Light Therapy Device listed under two model designations, XWYL-401A and XWYL-403A. The submission was received August 17, 2026, reviewed under the Traditional pathway without third-party review, and decided Substantially Equivalent on October 14, 2026. The file carries a Summary statement rather than a full summary or no statement. The applicant name appears in FDA's premarket notification listing alongside a Yulin, China mailing address, which is a filing address and not evidence of a headquarters location. [1][5][7]
The cleared device and its regulatory classification
K262885 names the 308nm Ultraviolet Light Therapy Device with model designations XWYL-401A and XWYL-403A. FDA assigns the device to product code FTC, regulation number 878.4630, and classification name Light, Ultraviolet, Dermatological, within device class 2. The advisory committee and review panel are both recorded as General, Plastic Surgery. The clearance type is Traditional and the third-party review flag is N. [1][5][6]
The decision code is SESE, described by FDA as Substantially Equivalent, with a decision date of October 14, 2026. The statement or summary field reads Summary. The submission date recorded by FDA is August 17, 2026, giving a review interval of roughly two months between receipt and decision. [1][5][7]
Filing details and applicant identity
FDA's premarket notification listing records the applicant as Guangxi Hope Medical Devices Technology Co., Ltd., with contact name Bing Wang and an address on the first and second floor of Building 3, Yulin Traditional Chinese Medicine, Yulin, postal code 537000, country code CN. The same listing carries the K262885 entry with the August 17 receipt date and October 14 decision date. [1][7]
The applicant name is the legal entity named in the FDA filing. No parent company, brand owner, manufacturing affiliate or corporate group is identified in the numbered records, and none should be inferred from the applicant name alone. The Yulin address is the address of record in the filing, not a verified corporate headquarters. [1][7]
What the collection shows, and what it does not
The linked collection contains one 510(k) record, and the decision count for that collection is one SESE. The smaller record sample likewise contains one entry, the same K262885 filing, so the sample and the collection denominators coincide here. These counts describe the filings retrieved as of the snapshot date; they are not a measure of total company sales, total product portfolio or safety performance. [1][8]
An independent index of FDA records, published by Arca, lists Guangxi Hope Medical Devices Technology with one 510(k) clearance as of November 19, 2026, the most recent dated October 14, 2026 for the 308nm Ultraviolet Light Therapy Device. That index also notes that some company attributes were labeled by a language model from FDA names, so those labels should be treated as third-party annotation rather than FDA data. [8]
Context within the ultraviolet phototherapy product code
Other clearances under product code FTC appear in the same public indexes. FDA.report lists K262285 for a UV Phototherapy Device from Shijiazhuang Recovery Star Medical Device Co., Ltd., decided October 5, 2026, and earlier Daavlin Distributing Co. clearances for phototherapy equipment. These are separate applicants and separate devices, cited only to show the product code's activity. [5]
An Innolitics record page for K262885 references a predicate device numbered K170489. The numbered sources do not describe that predicate device's identity or contents, so the comparison basis behind the Substantially Equivalent decision remains unknown from this material. No clinical performance, treatment claims or commercial availability information is established by the clearance record. [6]
